• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Learn Why The Bull Case For Encompass Health Stock Could Change Following Raised Full Year Guidance

    Simply Wall St·11/09/2026 08:22:07
    Listen to the news
    • Encompass Health reported third quarter 2026 sales of US$1,609.5 million and net income of US$149.9 million, with higher basic and diluted earnings per share from continuing operations compared with the same period a year earlier.
    • Management also raised full year 2026 net operating revenue guidance to a range of US$6,450 million to US$6,500 million. This reflects confidence in the current operating run rate and the integration of ongoing capacity expansion in markets such as greater Houston.
    • We will now explore how Encompass Health's raised 2026 revenue outlook may influence the existing investment narrative around capacity-led growth.

    Scan how Encompass Health's earnings story compares with other hospital and healthcare operators through a curated list of 35 healthcare AI stocks.

    Encompass Health Investment Narrative Recap

    To own Encompass Health, you need to be comfortable with a capacity led growth story that depends on filling new beds at attractive economics while keeping labor and reimbursement pressures in check. The analyst consensus Narrative on Simply Wall St leans on ongoing discharge volume growth and efficient ramp up of new facilities. The latest quarter, with higher sales, net income and earnings per share versus a year earlier, supports that execution story in the near term.

    The short term swing factor still looks like payer behavior and policy. Tougher Medicare Advantage pre authorization trends or further reimbursement adjustments, such as the Florida Medicaid tax change, could offset some of the benefit from higher volumes. Management's modestly higher 2026 revenue guidance suggests they currently see no material change to that risk balance from recent results.

    The guidance increase for 2026 net operating revenue to US$6,450 million to US$6,500 million ties most directly to the near term catalyst investors watch, which is whether Encompass Health can translate its expansion pipeline into sustained top line progress. That new range sits slightly above the prior outlook and anchors expectations around the current operating run rate.

    For anyone tracking catalysts, the Richmond, Texas small format hospital plan adds context. It illustrates how Encompass Health is leaning into compact facilities to extend reach in dense markets such as greater Houston, while still committing capital that must earn back against reimbursement and occupancy risks. Execution on this kind of project series, including ramp speed and staffing efficiency, remains central to the story that analysts have built into their forecasts.

    Encompass Health's current analyst narrative points to forecast revenue of about US$8.1b and projected earnings of US$893.7 million by 2029, based on an assumed 8.7% yearly revenue growth rate and an earnings increase of roughly US$266 million from current earnings of US$627.6 million.

    Uncover why Encompass Health's fair value indicates a 13% potential upside to its current price that could narrow quickly.

    NYSE:EHC 1-Year Stock Price Chart
    NYSE:EHC 1-Year Stock Price Chart

    Exploring Other Perspectives

    Four fair value estimates from the Simply Wall St Community range from about US$99 to roughly US$245 per share for Encompass Health, so opinions already stretch from cautious to very optimistic. Compare these pre earnings views with the tighter 2026 revenue guidance and ongoing payer and reimbursement risks, then explore how differently other investors weigh those trade offs.

    Explore 3 other Encompass Health fair value estimates, including one that suggests up to 78% potential upside from the current price.

    Form Your Own Verdict

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Encompass Health?

    If Encompass Health is on your radar, it can help to compare it with a few other opportunities that fit different risk and return profiles. Use the Simply Wall St Screener to line up similar stocks by quality, balance sheet strength, or income potential, then see how the numbers stack up side by side.

    • For investors who care most about capital strength and cleaner financials, start with a list of solid balance sheet and fundamentals (25 results) that lets you focus on companies built on sturdier foundations.
    • If income is a priority and you want yields above 5% backed by more resilient businesses, zero in on a shortlist of 7 dividend fortresses that prioritizes cash payouts without ignoring stability.
    • When you are hunting for quality that may not yet be widely followed, scan through 19 high quality undiscovered gems and see which under-the-radar stocks match your return and risk preferences.